



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Folutyn™

Common Name: Pralatrexate

PDL Category: Antineoplastics-Antimetabolites

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Doxorubicin	Recommended
Vincristine	Recommended

Summary

Indications and Usage: Treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).¹

Mechanism of Action: Inhibits dihydrofolate reductase (DHFR), which disrupts the building of DNA within a tumor.¹

Dosage Forms: Injection: 20mg/ml

Recommended Dosage: 30mg/m² administered as an intravenous push over 3 to 5 minutes once weekly for 6 weeks in 7-week cycles.¹

Common Adverse Drug Reactions: Mucositis, thrombocytopenia, fever, nausea, and fatigue.¹

Contraindications: None.¹

Manufacturer: Allos Therapeutics, Inc.

Analysis: Folutyn™ received accelerated FDA approval for the treatment of PTCL in patients who have relapsed or have not responded well to other forms of chemotherapy. In the trial used to gain FDA approval, Folutyn™ reduced tumor size in 27% of patients with a median duration of response of 287 days (9.4 months). It is recommended that Folutyn™ be added to the Preferred Drug List as a recommended drug.

IME Recommendation: Preferred Drug Recommended Drug
 Non-Preferred Drug Non-Recommended Drug
 Preferred Drug with Conditions

1. Folutyn™ [package insert]. Westminster, CO: Allos Therapeutics, Inc.; 2009.